## Abstract ## Objectives/Hypothesis: Previous studies have demonstrated a relationship between elevated serum squamous cell carcinoma (SCC) antigen (SCC‐Ag) levels and shorter survival in cancer patients. Few studies, however, have investigated the role of serum SCC‐Ag levels in oral SCC (OSCC).
Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells
✍ Scribed by Yukio Yamano; Masashi Shiiba; Kenji Negoro; Ken Nakatani; Atsushi Kasamatsu; Masanobu Yamatoji; Kentaro Sakuma; Kenji Ogoshi; Manabu Iyoda; Keiji Shinozuka; Hidetaka Yokoe; Takeshi Wada; Shigeyuki Fujita; Shunichiro Iwasawa; Yuichi Takiguchi; Hideki Tanzawa; Katsuhiro Uzawa
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 529 KB
- Volume
- 33
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background.
The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP)‐resistant oral squamous cell carcinoma (OSCC) cell line and its parental cell line.
Methods.
CDDP‐resistant (KB‐R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real‐time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment.
Results.
KB‐R cells did not show cross‐resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB‐R cells. There was no difference in the GSH levels between the KB and KB‐R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB‐R cells. KB‐R cells contain enriched side population cells.
Conclusion.
These data suggested that satraplatin has antitumor activity against the CDDP‐resistant OSCC cells. The mechanism of cross‐resistance to platinum agents seems to be multifactorial. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
📜 SIMILAR VOLUMES
## Abstract Resistance to cisplatin is a major obstacle to successful treatment of head and neck squamous cell carcinoma (HNSCC). To investigate the molecular mechanism of this resistance, we compared the gene expression profiles between the cisplatin‐sensitive SCC cell lines (Sa‐3, H‐1 and KB) and
## Abstract Intensity of mononuclear cell infiltrates in 50 oral cancer tissues was evaluated by immunohistochemical stainings. The intensity of the infiltrates was graded into four degrees from marked (+ + +) to absent (‐); and the degree of each infiltrated lymphocyte subpopulation including Leu‐
The ABH isoantigen was investigated in 80 patients with squamous cell carcinoma of the oral cavity and in their 46 affected lymph nodes. Isoantigen deletion shows a characteristic pattern of benign to malignant transformation of oral cancer. Total loss of isoantigen was found in anaplastic tumours,
## Abstract A human oral squamous‐cell‐carcinoma cell line, HOC313, was found to produce a factor which stimulates cell motility in an autocrine manner. The motility factor of HOC313 cells also promoted the locomotory activity of B16 murine melanoma cells reported to be sensitive to autocrine motil
## Abstract ## Background Resistance to chemotherapy is a major limitation in the treatment of head and neck squamous cell carcinomas (HNSCCs), accounting for high mortality rates in patients. Here, we investigated the role of replication protein A (RPA) in cisplatin and etoposide resistance. ##